• Alumis released topline results from the LUMUS Phase 2b trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus.
• Study missed primary endpoint of BICLA response at week 48 across the overall population; placebo response was elevated.
• Placebo BICLA response was 35.7% versus 40%-42.2% for envudeucitinib; p-values ranged from 0.35 to 0.5.
• Prespecified IFNGS-high subgroup showed stronger outcomes; BICLA response reached 52.6% on 40 mg BID versus 28.6% for placebo.
• Safety profile appeared favorable; no new safety signals reported, with lower adverse-event rates on active treatment versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.